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We have previously shown that the aptamer, UCLA1, is able to inhibit HIV-1 replication in peripheral
blood mononuclear cells (PBMCs) by binding to residues in gp120. In this study we examined whether
UCLA1 was effective against HIV-1 subtype C isolates in monocyte-derived macrophages (MDMs). Of
4 macrophage-tropic isolates tested, 3 were inhibited by UCLA1 in the low nanomolar range
(IC80o29 nM). One isolate that showed reduced susceptibility (o50 nM) to UCLA1 contained mutations
in the α5 helix next to the CD4 and co-receptor (CoR) binding complex. To further evaluate aptamer
resistance, two primary viruses were subjected to increasing concentrations of UCLA1 over a period of 84
days in PBMCs. One isolate showed a 7-fold increase in IC80 (351 nM) associated with genetic changes,
some of which were previously implicated in resistance. This included F223Y in the C2 region and P369L
within the CD4 and CoR binding complex. A second isolate showed a 3-fold increase in IC80 (118 nM) but
failed to show any genetic changes. Collectively, these data show that UCLA1 can efﬁciently block HIV-1
infection in MDMs and PBMCs with escape mutations arising in some isolates after prolonged exposure
to the aptamer. This supports the further development of the UCLA1 aptamer as a HIV-1 entry inhibitor.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The AIDS epidemic is a major global health crisis with over 36
million people living with HIV and high rates of new infections in
many countries (www.who.int/hiv/en). HIV-1 subtype C is the
most dominant viral subtype found mostly in sub-Saharan Africa
and India with over 70% of new global HIV infections occurring in
these regions. While the development of a vaccine is considered
essential to control the HIV epidemic, this has proven to be a major
challenge largely due to the high genetic variability and evolu-
tionary rates of HIV [1]. The widespread use of anti-retroviral
therapy has had a signiﬁcant impact on the epidemic with over 15
million people currently being treated. However, anti-retroviral
drugs trigger viral evolution and select for resistance [2,3] and as
such newer drugs and agents need to be developed.
UCLA1 is a shortened and modiﬁed RNA aptamer derived fromB.V. This is an open access article u
handu),
u.au (E.S. Gray),
hati).
ol of Medical Sciences, Joon-the parental B40 aptamer [4,5]. This molecule has been shown to
bind to HIV-1 gp120 with high speciﬁcity and afﬁnity and to po-
tently inhibit HIV-1 subtype C entry. Our previous study revealed
UCLA1 binding sites within the CoR binding site, at the base of the
V3 loop, and in the bridging sheet within the conserved V1/V2
stem-loop of gp120 [6]. As a promising anti-HIV-1 candidate,
UCLA1 may complement existing ARV regimens or be used in HIV
prevention strategies, such as a microbicide. The study of re-
sistance against any inhibitor of HIV-1 is necessary to identify the
nature and number of mutations associated with viral escape. It
also enables studies to assess the prevalence of naturally-occurring
resistant strains and hence the likelihood of efﬁcacy.
In addition to CD4þ T lymphocytes, HIV-1 infects blood
monocytes and tissue macrophages which are thought to play an
important role in the maintenance of viral reservoirs [7,8]. Fur-
thermore, these cells may play a role in HIV-1 transmission at
mucosal sites. Thus potential entry inhibitors of macrophage in-
fection could not only block the transmission of HIV at mucosal
surfaces but also prevent seeding of reservoirs. Thus, the current
study examined UCLA1 inhibition efﬁcacy against HIV-1 subtype C
clinical isolates in MDMs and evaluated the generation of UCLA1
escape mutations in PBMCs.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Isolation of monocyte-derived macrophages
Macrophages were derived from blood monocytes [9]. Brieﬂy,
PBMCs were freshly isolated from HIV-seronegative blood donors
using the Ficoll-Hypaque method [10] and re-suspended in Lonza
X-VIVO-10 culture media (Whitehead Scientiﬁc, S.A), supple-
mented with 10% fetal bovine serum (FBS, Gibco Invitrogen, South
Africa). Cells were incubated for 90 min at 37 °C in 5% CO2 in T150
ﬂasks and washed to remove non-adherent cells. The adherent
monocytes were incubated overnight in the supplemented
X-VIVO-10 media and the monolayer disrupted by adding chilled
PBS at 4 °C for 1 h [11]. Re-suspended monocytes were cultured in
Rosewell Park Memorial Institute (RPMI) medium supplemented
with 10% FBS (10% RPMI growth media) and 5 ng/ml human
granulocyte macrophage colony stimulating factor (hGM-CSF)
(Roche Diagnostics, Mannheim, Germany) for 5–7 days to enable
differentiation into macrophages.
2.2. Phenotypic characterization of monocyte-derived macrophages
Phenotype conﬁrmation of the differentiated macrophages was
performed by ﬂuorescence activated cell sorting (FACS) analysis
[9,11]. Brieﬂy, the macrophages were ﬁxed and indirect cell surface
staining performed with CD14/AF514 MAbs (Whitehead Scientiﬁc,
S.A, Invitrogen Life Technologies, S.A) which stained un-
differentiated monocytes, CD68/AF488 or MHCII/AF488 MAbs
stained differentiated monocytes (macrophages) and CD3/PE-
Cy5.5 (Caltag Laboratories, Thailand) stained T lymphocytes. The
cells were acquired on the BD FACSCalibur ﬂow cytometer (Im-
munocytometry Systems, CA, USA) and analysed with the BD
CellQuest Pro software, version 5.1 (BD Biosciences, NJ, USA).
2.3. Screening of macrophage-tropic viruses
A panel of 25 HIV-1 subtype C replication competent primary
isolates were screened for macrophage tropism. These included
four viruses from the CAPRISA 002 Acute Infection study cohort
[12], ﬁve from the Durban female sex workers cohort [13], eight
paediatric isolates [14], ﬁve from HIV/TB co-infected patients and
three AIDS patients co-infected with Cryptococcus meningitis [15].
Twenty of the viruses were R5, four were R54 [14,15] and one
X4 virus [15]. An R5-tropic subtype B primary virus, ADA, known
to infect macrophages was used as a reference strain. Brieﬂy, viral
stocks were grown in 2106 PBMCs which were CD8 T cells de-
pleted using the RosetteSep human CD8 depletion cocktail method
(Separation Scientiﬁc, South Africa). The cells were re-suspended
in RPMI medium plus 20% FBS, 50 μg/ml gentamicin (Sigma-Al-
drich, South Africa) and 5% IL-2 (Roche, South Africa) (complete
medium). Phytohemagglutinin (PHA) (Sigma-Aldrich, South Afri-
ca) was added to the media for activation of the lymphocytes.
Culture supernatants were tested weekly for p24 antigen using the
Vironostika HIV-1 Antigen Microelisa System (Biomerieux, South
Africa) and expanded when high levels of p24 antigen (100–
200 ng/ml) were present. Cultures were fed twice weekly with
complete medium and weekly with fresh PHA-activated donor
PBMCs for 3 weeks. Virus-containing supernatants were clariﬁed
by centrifugation and stored at 70 °C until use.
2.4. HIV-1 infection of MDMs
MDMs (0.5–1.0106 cells/ml) were infected with 500–2500
TCID50 of the primary viruses in 24-well tissue culture plates and
incubated overnight at 37 °C, 5% CO2 [9]. Control wells with only
cells and media were included. Virus inoculum was aspirated andthe cells washed with 10% RPMI growth media. The cells were
then re-suspended in 10% RPMI growth media and incubated for a
further 6 days at 37 °C, 5% CO2. The cultures were harvested every
7th day and maintained for a maximum of 42 days.
2.5. Neutralization of HIV-1 in MDMs
Neutralization of HIV-1 subtype C infection in MDMs by UCLA1
anti-gp120 RNA aptamer was done as previously described for
PBMCs [9]. Brieﬂy, UCLA1 was used at a starting concentration of
100 nM with 3-fold serial dilutions in RPMI supplemented with 5%
FBS (growth media). Virus supernatants at 500–2500 TCID50 were
added to the serially diluted aptamer and incubated for 1 h at
37 °C, 5% CO2. Differentiated macrophages were seeded at 1.0106
cells/ml in 96-well culture plates. Half of the volume of the cell
supernatants was aspirated and the aptamer/virus mix added to
the cells and incubated overnight at 37 °C, 5% CO2. The assay was
performed in triplicate and included control wells without apta-
mer. The cells were washed 3 times by aspirating the virus in-
oculum from each well and adding 250 ml of RPMI growth media.
The cells were then incubated for a further 6 days in RPMI growth
media at 37 °C, 5% CO2. On day 7, 50 ml of virus supernatants were
harvested from each well and the cultures replenished with an
equal volume of RPMI growth media and incubated at 37 °C, 5%
CO2 for a further 7 days. The supernatants were harvested every
7th day for a maximum of 21 days. The harvested viral super-
natants were inactivated with 1.25% Empigen BB detergent and
stored at 4 °C in zip-lock plastic bags until further use.
2.6. HIV-1 p24-antigen immunoassay
Macrophages were evaluated for infection and neutralization
using the HIV-1 chemiluminescent p24 antigen ELISA as pre-
viously described [16]. Brieﬂy, p24 antigen was captured from a
detergent lysate of virions by a polyclonal antibody adsorbed to
96-well plate. Bound p24 was detected with an alkaline phos-
phatase-conjugated anti-p24 MAb and a luminescent detection
system. Luminescence was measured with the Wallac 1420 Victor
Multilabel luminometer (Separation Scientiﬁc, S.A). The neu-
tralization titers were determined at 70% level of reduction in p24
antigen production of the test cultures compared with the nega-
tive control cultures (without inhibitor).
2.7. Evaluation of resistance to UCLA1
Two primary isolates that showed different co-receptor usage,
RP1 (R54-tropic) and Du422 (R5-tropic) were used to evaluate
resistance to the aptamer. Both viruses were shown to be sensitive
to UCLA1 in PBMCs in the previous study [6]. For this, 1000 TCID50
of each virus was cultured in the presence of increasing con-
centrations of the aptamer in 1106 CD8-depleted PBMCs. The
starting concentration of the aptamer was the IC80 of each virus
tested. Virus cultures without UCLA1 were used as negative con-
trols. All cultures were maintained in 5% RPMI growth media
supplemented with 0.05 μg/ml of IL-2. The cultures were passaged
every 7th day and new cultures set up with 10% of the harvest
from the previous culture in freshly isolated CD8-depleted PBMCs.
UCLA1 concentration was increased whenever the viral growth,
measured by p24 antigen ELISA, was similar or higher than the
negative control cultures.
2.8. Isolation, ampliﬁcation and sequencing of HIV-1 RNA
Isolation of viral RNA from cultures was performed with the
QIAamp mini spin viral isolation kit (QIAGEN, S.A). The extracted
RNA was reverse transcribed into cDNA using OFM19 primer:
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III reverse transcriptase (Invitrogen). The envelope gene was am-
pliﬁed by nested PCR using the High Fidelity Platinum Taq DNA
polymerase (Invitrogen) as described previously [17]. The ampli-
ﬁed DNA was puriﬁed with the QIAquick PCR puriﬁcation Kit
(QIAGEN), quantiﬁed and sequenced using an ABI PRISM Big Dye
Terminator Cycle Sequencing Ready Reaction kit (Applied Biosys-
tems, S.A). The sequences were resolved on an ABI 3100 auto-
mated genetic analyzer and were assembled and edited using
Sequencher (version 4.0), (Gene Codes, Ann Arbor, MI), Clustal X (v
1.83) and Bioedit (v 5.0.9) software.3. Results
3.1. Screening for macrophage-tropic viruses
Puriﬁed populations of macrophages were derived from blood
monocytes after culture in hGM-CSF. Surface staining with either
MHC Class II or CD68 mAbs conﬁrmed that 99.9% of the monocytes
had differentiated into macrophages (Supplementary Figure 1A
and B). Twenty-ﬁve HIV-1 subtype C primary viruses were
screened for macrophage tropism with 410 ng p24 indicative of
viral replication (Supplementary Table 1). Five isolates showed an
increase in p24 antigen levels over the 42 days of culture (Fig. 1A),
and were considered to be macrophage-tropic viruses. Peak p24
titers were in the range of 20.7–107.8 ng at 21 days of infection for0 7 14 21 28 35 42 49
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Fig. 1. Infectivity of HIV-1 primary viruses in monocyte-derived macrophages
(MDMs). (A): Screening of HIV-1 subtype C primary isolates for macrophage in-
fectivity. (B): Infectivity of macrophage tropic HIV-1 subtype B ADA primary virus.
Viruses were cultured for a maximum of 42 days to evaluate their infectivity in
MDMs. Infectivity was measured as HIV-1 Gag p24 production using supernatants
that were harvested weekly.four of the isolates. Du156 showed the lowest levels of infection
with a peak p24 concentration of 3.7 ng/ml on day 35. Conse-
quently, 4 subtype C isolates (CM1, COT9, Du422 and SW14) were
used to evaluate UCLA1 neutralization in MDMs. The subtype B
isolate, ADA, was included as a macrophage-tropic reference
strain. This virus showed the highest levels of replication with a
p24 value peaking at 407.9 ng a week earlier on day 14 (Fig. 1B).
3.2. Neutralization of HIV-1 primary isolates in MDMs
The UCLA1 aptamer was tested at a starting concentration of
100 nM against 4 HIV-1 subtype C R5-tropic viruses. This was in-
formed by our previous data where the same concentration was
tested against HIV-1 subtype C primary viruses in PBMCs [6].
Three viruses tested in MDMs were neutralized in a dose-depen-
dent manner with IC80 values in the range of 6–29 nM (Fig. 2). A
fourth isolate, CM1 was neutralized but the inhibition was not
high enough to obtain an IC80 value and was considered to have
reduced susceptibility. Examination of gp160 sequence of this
isolate revealed R476K, V491I, N492K, V496I and K500S mutations
in the α5 helix next to the CD4 and CoR binding complex which
may have contributed to the reduced susceptibility (Supplemen-
tary Figure 2). The subtype B isolate (ADA) was neutralized with an
IC80 value of 30 nM in MDMs.
3.3. Generation of UCLA1 resistant isolates
We next assessed whether UCLA1 was able to select for viral
resistance in vitro. Two primary isolates, RP1 (R54-tropic) and
Du422 (R5-tropic), that were inhibited by UCLA1 in PBMCs in the
previous study [6], were cultured in PBMCs with escalating con-
centrations of the aptamer for 84 and 77 days, respectively (Fig. 3).
Control cultures without aptamer were also assessed. Culture su-
pernatants were collected once a week and tested for p24 antigen
levels. The viral growth pattern varied during resistance selection
and in some instances was markedly reduced when compared
with the control cultures thus conﬁrming UCLA1 anti-HIV activity
in the test cultures (Fig. 3 and Supplementary Tables 2A and 2B).
For example, this was observed for RP1 at day 35 where the p24
for the test culture (with UCLA1) was 6-fold (3.8 ng/ml) less than
the control culture (25.2 ng/ml) (Fig. 3 and Supplementary
Table 2A). The IC80 values for RP1 and Du422 at the end of selec-
tion period was 351 nM and 118 nM, that is, 7-fold and 3-fold re-
spectively compared to p24 values before selection (Table 1).
3.4. Sequence analysis of UCLA1-selected isolates
Viral RNA from the culture supernatants were used to sequence
the gp160 gene to assess for mutations within the env gene that
might have occurred due to the selective pressure from UCLA1. No
mutations were generated in the Du422 isolate, including the
control culture, despite its ability to tolerate slightly increased
UCLA1 concentrations. Six mutations were detected in RP1, at the
base of the V3 loop (R322Q), within the V4 loop (N410S), in β3 of
the bridging sheet next to the V1/V2 loop (R202T), in the C2 region
between β4 and β5 sheets (F223Y), within the CD4 and CoR
binding complex in the α3 helix (P369L) and in the α5 helix next
to the CD4 and CoR binding complex within the β24 sheet (K476R)
(Fig. 4A and B). The P369L mutation was also present in the RP1
control virus cultured in the absence of aptamer.4. Discussion
The study examined the ability of the UCLA1 aptamer to inhibit
HIV-1 subtype C infection of primary isolates in MDMs and
Fig. 2. Representative dose-dependent neutralization graphs of HIV-1 subtype C primary isolates in MDM. UCLA1 aptamer was used at a starting concentration of 100 nM.
Neutralization was measured as a reduction in p24 production compared to the control without aptamer. The IC80 values were calculated as p24 antigen titers causing 80%
reduction of p24 antigen production compared with the virus control (without UCLA1). The assay was performed at least three times, in triplicate, for each primary isolate
tested. Statistical signiﬁcant difference of UCLA1 inhibition compared to the virus control was determined by t-test and indicated by asterisks where * and *** indicate p
values of less than 0.05 and 0.001, respectively. NS indicates no signiﬁcance.
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exhibited higher neutralization potency in MDMs compared to our
previous data with PBMCs. Viral resistance against UCLA1 neu-
tralization was evaluated by propagation under escalating con-
centrations of the aptamer. The selective pressure of UCLA1 re-
sulted in resistance of one of the two viruses tested although this
took time and was associated with multiple genetic changes in the
HIV-1 envelope gene.
Primary viruses were screened for macrophage tropism before
testing for UCLA1 inhibition. As expected, only R5-tropic primary
viruses were competent to infect MDMs as their co-receptor, CCR5,
serves as the major receptor on macrophages for HIV [18]. When
tested for antiviral activity in MDM cells, UCLA1 was able to inhibit
entry of all four subtype C macrophage-tropic primary isolates
tested. Its efﬁcacy was demonstrated to be more potent in MDMs
(IC80o29 nM) than in PBMCs (IC80o94 nM) [6]. The higher efﬁ-
ciency of UCLA1 against macrophages may be due to viral entry
determinants, such as CD4 binding which is lower in MDMs [19]. A
previous study identiﬁed V3 loop determinants of R5 macrophage-
tropism suggesting that a conformational change in the V3 loop
increased exposure of the CD4bs [19–21]. Given that we observed
binding of UCLA1 in the V3 loop [4,6] a similar exposure of the
CD4bs to UCLA1 might have occurred which may explain thehigher aptamer potency in MDMs. Blood monocytes and tissue
macrophages are known to function as virus reservoirs in vivo and
thus serve as obstacles to HIV clearance due to their contribution
to persistent HIV infection [11]. Therefore, UCLA1 an efﬁcient entry
inhibitor of macrophage infection, may be useful to eliminate the
burden of infection as well as limit the size of the virus reservoirs
although there are obstacles such as latently infected, resting
CD4þ T cells and persistence of HIV in infected individuals re-
ceiving antiretroviral therapy [22] to address before the aptamer
can be considered as a viral reservoir inhibitor.
Selection of RP1 resistance by UCLA1 in PBMCs resulted in a
7-fold increase in IC80 values and generation of genetic changes in
the envelope gene. Based on our previous data the F223Y mutation
within the C2 region has been shown to decrease binding of the
UCLA1 parental aptamer (B40t77) to HIV-1BaL gp120 [23] and
might also be an escape mutation. The P369L mutation in the C3
region was observed to confer resistance to UCLA1 inhibition by
site-directed mutagenesis in our earlier study [6]. However, P369L
was also present in the control virus that had no aptamer selection
pressure suggesting that it is unstable and occurs spontaneously.
An Arginine at residue 476 in the α5-helix selected in RP1 has
been identiﬁed as one of the essential sites of antibody gp120-core
binding and for optimal viral infectivity [24]. The site is highly
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Fig. 3. In vitro selection of UCLA1 resistant viruses. HIV-1 subtype C primary isolates (RP1 and Du422) were cultured in PBMCs with increasing concentrations of UCLA1 for a
maximum period of 84 days. The concentration of the aptamer was increased only when p24 production in the UCLA1 culture was the similar or higher than the control
culture. RP1 and Du422 were isolated and sequenced at day 77 and 84, respectively.
Table 1
Pre- and post-selection IC80 values of UCLA1 against HIV-1 primary isolates in
PBMCs.
Virus Pre-selection
IC80 (nM)
Post-selection
IC80 (nM)
IC80 fold
increase
Selection days
RP1 53.0 351.0 7 84
Du422 38.0 118.0 3 77
IC80 is the concentration of UCLA1 causing 80% inhibition of virus infection.
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occurring as R476 and mutating the epitope results in loss of in-
fectivity [24]. Therefore, the RP1 isolate may have generated the
K476R mutation in order to gain ﬁtness and survive the increasing
concentrations of UCLA1. R476 was also found to occur naturally in
CM1 and may have contributed to the reduced sensitivity seen in
this isolate. The R202T in the bridging sheet, R322Q in the V3 loop
and N410S in the V4 loop were observed for the ﬁrst time here but
their role requires further study. Thus, ﬁve mutations (R202T,
F223Y, R322Q, N410S and K476R) and the previously discovered
P369L mutation were identiﬁed in this study using in vitro selec-
tion with UCLA1 of a primary isolate. It will be important however
to conﬁrm these as UCLA1 escape mutations by site-directed
mutagenesis of Env-pseudotyped viruses as was done previously
for P369L [6] and also assess if escape in MDMs follows the same
pathways.
Overall, our results indicate that selection of mutations asso-
ciated with UCLA1 resistance required extended exposure to the
drug (3 months) probably due to the very low nanomolar con-
centration levels that were utilized. Since the current study,together with our previous study [6] has shown that the aptamer
is robust even at low nanomolar quantities, it may serve as a good
anti-HIV-1 entry inhibitor that requires lower concentrations of
the aptamer and thus cost effective as a product. This is the ﬁrst
study to report the in vitro generation of escape mutations, over a
period of 12 weeks, against anti-gp120 aptamers using primary
viruses. While only two isolates were studied here, they provide
important proof-of-principle data and identify key mutations for
validation. Thus, further studies with more primary isolates will
contribute to a better understanding of HIV-1 escape mechanism
from neutralizing aptamers.Competing interests
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Fig. 4. Selection of envelope mutations in RP1 after culture with UCLA1. (A): Amino
acid sequence alignment of RP1 propagated under increasing concentrations of
UCLA1 (RP1 UCLA1) compared with the wild-type RP1 sequence (RP1) and RP1
propagated without aptamer (RP1 Control). The amino acid changes that were ob-
served after propagation, at 84 days, are highlighted in red for RP1 UCLA1 sequence
and in green for the RP1 Control sequence. The numbering is according to the HxB2
sequence. (B): Structural representation of UCLA1 escape mutations generated under
increasing concentrations of the aptamer. Residues implicated in UCLA1 escape are in
red spheres and their locations within gp120 are mentioned in parenthesis. The
numbering is according to the HxB2 sequence. Coordinates were taken from the
structure of gp120JRFL core with V3 ligated with CD4 and X5 (Protein Data Bank
accession no. 2B4C). The X5 antibody is removed from the depicted structure. Gp120
is represented in green and CD4 in magenta. The structure was generated with Py-
MOL (DeLano Scientiﬁc LLC, South San Francisco, CA [http://www.pymol.org]).
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